复发难治性AML的治疗-金洁
Dr. Solh and colleagues found that the factors associated with postremission survival included age at first CR, NCCN risk, induction regimen (FLAG+/-Ida vs. 7+3; hazard ratio, 0.62; P = .01), and receipt of allogeneic hematopoietic cell transplantation. "FLAG-Ida is a more efficacious reg...
Most common induction regimen was "7+3" (48%), followed by "7+3+GO" (37%), with 36% receiving gemtuzumab ozogamicin (GO) in consolidation (median- 3 cycles). CBF-MRD negativity was 15% at the end of induction, which increased to 70% after consolidation, with no significant ...
Patients with AML who do not achieve remission with conventional 7+3 induction chemotherapy can frequently achieve CR with an intensive reinduction regimen such as Ida-FLAG. However, when Ida-FLAG is used as the initial induction regimen, the outcome of patients who do not achieve remission and...
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimen and analysis of prognostic factors. Blood 1996; 87: 51–58. 12 Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A et al. On behalf of the Chronic Leukemia Working Party of ...
For decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7+3 regimen). In August 2017 the US FDA approved CPX-351 (vyxeos), a liposomal formulation of cytarabine and daunorubicin at a fixed 5:1 molar ratio,...
7+3 chemotherapyStem cell nicheCancer stem cellComputational modelMathematical modelAcute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The "7+3 regimen...
Recently published studies have explored the efficacy and tolerability of decitabine and venetoclax as a favorable alternative regimen in older adults with AML. However, there has not yet been a head-to-head study in the literature comparing real world outcomes for both regimens. Here we present ...
Understanding the intricacies of the pathophysiology and genomic landscape has enhanced the long-term outcomes for patients with acute myeloid leukemia (AML). The identification of novel molecular targets has introduced new therapeutic strategies that attempt to surpass the dominance of the "7+3 regimen...
Fifty years have passed since the development of the first chemotherapy regimen for treating acute myelogenous leukemia (AML), with the approval in 1973 of the cytarabine daunorubicin (7 3) regimen. Until recently, patients diagnosed with AML had very limited treatment options and depended primarily...